Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AEROLATE III vs NASACORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Triamcinolone acetonide, a corticosteroid, exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production, thereby decreasing nasal inflammation.
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
Allergic rhinitis (seasonal and perennial) approved by FDA
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
110 mcg (2 sprays) per nostril once daily; maximum: 440 mcg (4 sprays) per nostril once daily. Intranasal administration.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Terminal elimination half-life is approximately 3-4 hours after intranasal administration; however, due to prolonged residence time in nasal mucosa, clinical effects persist beyond plasma half-life.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Primarily hepatic via CYP3A4; main metabolites are 6β-hydroxytriamcinolone acetonide and 21-carboxylic acid derivative.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Primarily hepatic metabolism via CYP3A4; renal excretion accounts for <5% of unchanged drug; biliary/fecal excretion of metabolites accounts for ~60% of total clearance.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Approximately 99% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Vd is approximately 2-3 L/kg, indicating extensive tissue distribution; clinical significance: large Vd suggests sequestration in tissues, potentially prolonging retention.
Oral: 40-50%; Inhalation: 20-30%
Intranasal: Absolute bioavailability is approximately 3-5% due to extensive first-pass metabolism and limited absorption from nasal mucosa.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
No dosage adjustment required for renal impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
No specific dosage adjustment provided; use with caution in severe hepatic impairment, monitor for systemic effects.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Ages 2-5: 55 mcg (1 spray) per nostril once daily, maximum 110 mcg (2 sprays) once daily. Ages 6-11: 110 mcg (2 sprays) per nostril once daily, maximum 220 mcg (4 sprays) once daily. Ages 12+: same as adult.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No specific adjustment; use lowest effective dose due to potential increased systemic sensitivity; monitor for adverse effects.
No FDA black box warning.
No FDA black box warning.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Nasal septal perforation,Nasal irritation,Epistaxis,Candida albicans infection,Immunosuppression,Growth suppression in children,Hypothalamic-pituitary-adrenal axis suppression with prolonged use
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Hypersensitivity to triamcinolone acetonide or any excipient,Untreated localized nasal infection
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
No significant food interactions known. However, grapefruit juice may slightly increase systemic exposure; avoid excessive consumption.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at relatively low doses. There are no adequate and well-controlled studies in pregnant women. Nasacort should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Risk cannot be ruled out; avoid unless clearly needed. Second and third trimesters: Limited data; use with caution. Potential fetal risks include orofacial clefts (conflicting data), intrauterine growth restriction, and adrenal suppression in neonates with prolonged maternal use of high doses.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
It is not known whether triamcinolone acetonide is excreted in human breast milk. Because other corticosteroids are excreted in human milk, caution should be exercised when Nasacort is administered to a nursing woman. The M/P ratio is unknown. Low doses via intranasal route are unlikely to produce significant systemic levels; however, consider risk-benefit.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
No specific dosing adjustments are recommended for pregnancy based on pharmacokinetic changes. Use the lowest effective dose. Increased plasma volume and altered metabolism during pregnancy may decrease systemic exposure, but intranasal application minimizes systemic absorption. No dose adjustment is typically required, but clinical monitoring for efficacy is advised.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
For optimal efficacy, prime the nasal spray by actuating 5 times or until a fine mist appears. If not used for 7+ days, re-prime with 2 actuations. Instruct patient to blow nose gently before use and tilt head slightly forward. Avoid spraying directly onto nasal septum to reduce risk of epistaxis. May cause growth suppression in children; monitor height regularly if long-term use. Onset of action is within 12-24 hours, but maximal effect may take 2-3 weeks.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
Use regularly for best results; it may take 2-3 weeks for full effect.,Blow your nose gently before each use to clear nasal passages.,Do not spray directly onto the nasal septum (the wall between nostrils).,Clean the nozzle after each use and replace the cap tightly.,If you miss a dose, skip it and continue with the next scheduled dose; do not double the dose.,Common side effects include nosebleeds, headache, and nasal irritation.,Report persistent nosebleeds, vision changes, or signs of infection (e.g., fever) to your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AEROLATE III vs NASACORT, answered by our medical review team.
AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. NASACORT is a Intranasal Corticosteroid that works by Triamcinolone acetonide, a corticosteroid, exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production, thereby decreasing nasal inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AEROLATE III and NASACORT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. The standard adult dose of NASACORT is: 110 mcg (2 sprays) per nostril once daily; maximum: 440 mcg (4 sprays) per nostril once daily. Intranasal administration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AEROLATE III and NASACORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. NASACORT is classified as Category C. FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at relatively low doses. There are no adequate and well-controlled studies in pregnan. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.